Overview

Download the Presentation as a PDF

Esketamine (Spravato) was approved by Health Canada for treatment resistant depression in 2020. It is the first medication in its class available for this indication. This presentation will review the potenital role of esketamine in the treatment of major depressive disorder. 

Objectives

As a result of attending this session, participants will be able to:

• Know the definition of treatment resistant depression
• Know the risks and benefits of esketamine
• Understand barriers and challenges involved in using esketamine in clincial practice 

Recommended Reading Websites